UNLEASHING THE FULL POTENTIAL
OF PSYCHEDELIC MUSHROOMS
WE ARE PSYGA BIO
PsygaBio is a drug discovery company focused on developing groundbreaking therapeutics derived from natural compounds. Founded by world-renowned cannabis and mushrooms researcher and pioneer Prof. Dedi Meiri from the Technion – Israel Institute of Technology and backed by robust scientific capabilities.
PsygaBio using Cannasoul’s proprietary analytical platform, data-driven approach, unique knowhow and clinical trial framework supports active compound identification and development, from mushrooms cultivation and extraction for clinical approved formulations.
OUR MISSION
DISCOVERING EFFECTIVE AND INNOVATIVE THERAPIES
FROM PSYCHEDELIC MUSHROOMS
OUR DEVELOPMENT METHODOLOGY
GENETIC
DIVERSITY
CHEMICAL
ANALYTICS
ISOLATIONS
AND SYNTHESIS
FUNCTIONAL
BIOLOGICAL SCREENING
CLINICAL
TRIALS
Psilocybin and psilocin, major active metabolites in psychedelic mushrooms are gaining attention as potential therapy for many psychiatric conditions. These molecules are a part of a variety of tryptamine alkaloids, found in mushrooms, analogs to the naturally occurring neurotransmitter molecule Serotonin. Serotonin and serotonin receptors are important in the regulation of virtually all brain functions and many more of the body’s organs and systems such as immune responses, heart, kidneys and the digestive system.
PsygaBio in partnership with Cannasoul analytics aims to exploits the diversity found in the psychedelic mushroom realm to identify active compounds and formulations for therapeutic benefits.
Revolutionizing Mental Health with Botanical Solutions
PsygaBio is on a mission to replace outdated SSRIs with our proprietary, botanical-derived molecules. Harnessing the therapeutic power of psilocybin mushrooms, our solutions offer unparalleled benefits.
PSYGABIO SCIENTIFIC CAPABILITIES
GENETIC DIVESITY
EXTRACTION, ISOLATION
SYNTHESIS OF SMALL MOLECULES
CHEMOANALYTICS
BIOLOGICAL SCREENING
HIGHLY EXPERIENCED MANAGEMENT
AND R&D TEAM
Dr. Shmuel Mandel
15 years of experience leading medical companies, Former VP Marketing & BD at DNR Bio Imagine, CEO & VP Marketing at AptaTeck Bio, VP of M&S at Rhenium, PhD in biochemistry and neuroscience
Prof. Dedi Meiri
Leading KOL in cannabis research, Head of the Cancer Biology and Cannabinoid Research Lab, Technion, Heads up Cannabis DB project, MSc in biochemistry, PhD in plant biology, Post doc at Ontario Cancer Institute
Dr. Isaac (Tzachy) Tal
CEO
Dr. Tal brings diverse entrepreneurial and scientific experience in biochemistry and molecular biology to the Psyga leadership team. Prior to Psyga, Dr. Tal was co-founder and CEO of Tamarix Pharma ltd developing novel technologies that restore physiological balance in apoptosis-related diseases, and co-founder and CEO of TPCera Ltd., which focused on developing novel immunomodulatory compounds to treat autoimmune diseases. During his tenure, Dr. Tal raised seed and round A funding to support the company’s technological, regulatory, clinical, financial, production, marketing, and business development activities. Dr. Tal was also the CEO of Gynamics, where he led all strategic and financial initiatives to advance the company’s medical device toward CE and FDA approval. Prior to his roles in the biotechnology industry, Dr. Tal served as Director of Business Development for the Technion – Israel Institute of Technology and for the Alfred Mann Institute for Biomedical Innovation.
Dr. Tal holds a PhD in Biochemistry and an MBA with specialization in Entrepreneurship and Finance from the Hebrew University of Jerusalem.
Dr. Rotem Perry Feigenbaum
Extensive experience in analytical research, Over 10 years of R&D expertise, Former head of analytical dpt. at Virdia, PhD in organic chemistry
Dr. Yaniv Lerenthal
Extensive experience in plant and human genomics and cancer research. Former R&D lead at bioinformatics lab at Kaiima bio agritech. Experienced in bioinformatics and data science. PhD in human genetics and cellular biology. Post doc at the cancer research center, Sheba medical center
Ido Taran
Experience in fungal physiology and molecular biology. Specializes in mushrooms cultivation. MSc in microbiology and fungal physiology
Looz Milay
Project manager in the Cannabis and psychedelic mushrooms R&D field with extensive experience in development of extraction technologies and chemical analytics. MSc from the Technion in Prof. David (Dedi) Meiri’s lab
Liron Sulimani
Head of Bioanalytics and Development
Extensive background in various techniques in the analytical chemistry, Bioanalytical testing and identification of unknown compounds using high-end technology, especially Mass-Spectrometry. PhD candidate in the faculty of Biology, Technion, Israel.